Ann: Appendix 4E and Full Year Statutory Accounts, page-2

How good is this, Imugene's "Principal activities" now extend down half a page!!!

"Principal activities -

The group is an Australian immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.

Lead products under development by the group are HER-Vaxx, PD1-Vaxx (formerly KEY-Vaxx), CF33 and CF33CD19.

HER-Vaxx is a proprietary HER2-positive cancer vaccine that stimulates a polyclonal antibody response against the HER2/neu receptors which are prevalent in breast cancer and gastric cancer.

PD1-Vaxx a cancer vaccine which aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibiting monoclonal antibodies that are transforming treatment for a range of cancer indications.

CF33 is a is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus.

CF33 CD19 directs chimeric antigen receptor (CAR) T cells therapies to target solid tumour."